{"url_path":"/sec/klrs/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1754068/0001193125-26-219328-index.html","accession_number":"0001193125-26-219328","cik":"0001754068","ticker":"KLRS","issuer_name":"Kalaris Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1754068/0001193125-26-219328-index.html","primary_entity_key":"0001754068","primary_entity_name":"Kalaris Therapeutics, Inc."},"word_count":441,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n2.1+\n\n \n\n[Agreement and Plan of Merger, dated as of November 7, 2024, by and among the Registrant, Aurora Merger Sub, Inc. and Kalaris Tx, Inc. (formerly, Kalaris Therapeutics, Inc.) (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39409) filed on November 8, 2024).](https://www.sec.gov/Archives/edgar/data/1754068/000119312524253747/d870301dex21.htm)\n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of the Registrant, dated March 18, 2025 (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-39409) filed on March 18, 2025).](https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex32.htm)\n\n3.2\n\n \n\n[Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K (File No. 001-39409) filed on March 18, 2025).](https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex33.htm)\n\n10.1\n\n \n\n[Common Stock Sales Agreement, dated April 3, 2026, by and between the Registrant and TD Securities (USA) LLC (incorporated by reference to Exhibit 1.2 to the Registrant’s Registration Statement on Form S-3 (File No. 333-294883) filed on April 3, 2026).](https://www.sec.gov/Archives/edgar/data/1754068/000119312526142199/d20326dex12.htm)\n\n31.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](klrs-ex31_1.htm)\n\n31.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](klrs-ex31_2.htm)\n\n32.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](klrs-ex32_1.htm)\n\n32.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](klrs-ex32_2.htm)\n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n* Filed herewith.\n\n+ The annexes, schedules, and certain exhibits to the merger agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.\n\n109\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nKalaris Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\n \n\nBy:\n\n/s/ Andrew Oxtoby\n\n \n\n \n\n \n\nAndrew Oxtoby\n\n \n\n \n\n \n\nPresident and Chief Executive Officer\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\n \n\nBy:\n\n/s/ Brett Hagen\n\n \n\n \n\n \n\nBrett Hagen\n\n \n\n \n\n \n\nChief Accounting Officer\n\n \n\n \n\n \n\n(Principal Financial Officer and Principal Accounting Officer)\n\n \n\n110"}